Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
Status:
Withdrawn
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the
progression free survival in patients with limited metastatic non-small cell lung cancer
(NSCLC). Treatment will be divided in two cohorts: patients eligible for ablative
stereotactic body radiotherapy to all metastatic sites (treatment with curative intent) and
patients not eligible for stereotactic body radiotherapy to all sites (life prolongation).
Phase:
Phase 2
Details
Lead Sponsor:
Maastricht Radiation Oncology
Collaborators:
Catholic University of the Sacred Heart Copenhagen University Hospital at Herlev Karolinska Institutet Katholieke Universiteit Leuven KU Leuven Maastricht University Medical Center The Netherlands Cancer Institute University of Oxford